Scarica l'app Stockscreener
79.28
1.84%
-1.49
Pre-mercato:
79.70
0.42
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Dexcom Inc Borsa (DXCM) Ultime notizie
What are analysts’ price targets for DexCom Inc. in the next 12 monthsCapitalize on stocks with high profit margins - jammulinksnews.com
How volatile is DexCom Inc. stock compared to the marketCapitalize on high-yield stock opportunities - jammulinksnews.com
Is it the right time to buy DexCom Inc. stockCapitalize on emerging market sectors - jammulinksnews.com
Is DexCom Inc. stock overvalued or undervaluedExceptional portfolio growth - jammulinksnews.com
What analysts say about DexCom Inc. stockTriple-digit returns - jammulinksnews.com
What institutional investors are buying DexCom Inc. stockOverwhelming financial success - jammulinksnews.com
Is It Time to Buy DexCom at a Discount Before Growth Fully Materializes? - AInvest
DexCom Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
How many analysts rate DexCom Inc. as a “Buy”Fastest-growing stock picks - jammulinksnews.com
How does DexCom Inc. generate profit in a changing economyMaximize your portfolio’s earning potential - jammulinksnews.com
DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands - MSN
Does DexCom Inc. stock perform well during market downturnsInvest smarter with real-time trading signals - jammulinksnews.com
What is the risk reward ratio of investing in DexCom Inc. stockInvest like a pro with expert recommendations - jammulinksnews.com
Investors Hope for Bounce in DexCom Inc. After SelloffValue Investing Picks With Stability Outlined - metal.it
DexCom (DXCM) Receives 'Buy' Rating from Canaccord Genuity | DXC - GuruFocus
Commit To Purchase DexCom At $50, Earn 6.2% Using Options - Nasdaq
DexCom, Inc. (NASDAQ:DXCM) Q2 2025 Earnings Call Transcript - Insider Monkey
Raymond James Maintains Buy Rating for Dexcom with $102 Price Target - AInvest
DexCom (DXCM) Q2 Revenue Jumps 15% - The Globe and Mail
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom raises sales expectations, discusses G8 plans - MedTech Dive
DexCom stock price target raised to $106 from $105 at UBS - Investing.com Australia
DexCom (DXCM) Sees Target Price Upgrade Post-Quarterly Results - GuruFocus
Dexcom: Raymond James Keeps Strong Buy, PT Raised to $102 from $99. - AInvest
DexCom (DXCM) Receives a Price Target Boost from Baird - GuruFocus
DexCom Q2 Earnings Beat Expectations, Raises 2025 Revenue Outlook - AInvest
Diabetes Care Devices Market Size Projects USD 76.44 Billion by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Price Target Raised by Oppenheimer to $102 | DXCM Stock News - GuruFocus
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise - Yahoo Finance
Dexcom, Inc. shares fall 4.70% premarket despite beating quarterly estimates and naming new CEO. - AInvest
DexCom Q2 2025 Earnings Call Transcript - MarketBeat
Dexcom Reports Strong Q2 2025 Growth and Leadership Change - TipRanks
DexCom Raises 2025 Revenue Guidance to $4.625B on Strong Type 2 Non-Insulin Access Growth - AInvest
Earnings call transcript: DexCom beats Q2 2025 expectations, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: DexCom beats Q2 2025 expectations, stock rises - Investing.com Australia
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Dexcom to promote COO Jake Leach to CEO, succeeding Kevin Sayer - MassDevice
Dexcom's Earnings Beat and Leadership Transition: Strategic Leadership Continuity and Growth Sustainability in the Diabetes Tech Sector - AInvest
DexCom Beats Q2 Revenue Estimates, Raises Full-Year Guidance - AInvest
DexCom: Q2 Earnings Snapshot - San Francisco Chronicle
Dexcom beats estimates for quarterly results, names new CEO - TradingView
Dexcom CEO Kevin Sayer to step down - MedTech Dive
DexCom's Earnings Beat and Strategic Leadership Shift: A Catalyst for Sustained Growth in the CGM Market? - AInvest
Dexcom falls despite results beat, revenue outlook raise (DXCM) - Seeking Alpha
DexCom Inc (DXCM) Q2 2025 Earnings: EPS of $0.45 Beats Estimate, Revenue Surges to $1.157 Billion - GuruFocus
DexCom posts strong Q2 results, announces CEO change; Shares fall 4% - Investing.com Nigeria
DexCom Q2 2025 slides: 15% revenue growth, FDA clearance for extended-wear G7 - Investing.com Canada
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan - Business Wire
DexCom (DXCM) Receives Target Price Upgrade from Barclays | DXCM Stock News - GuruFocus
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program | DXCM Stock News - GuruFocus
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program - The Joplin Globe
DexCom Inc. Shows Early Signs of Technical StrengthBuy Alerts With Low Risk Confirmation Noted - metal.it
DexCom Inc. Approaches Psychological Resistance LevelTop Gaining Picks With Entry Signals Identified - metal.it
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? - MSN
Dexcom Unveils AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio - AInvest
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
2.06%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):